Condition: Hyperphosphatemia · Chronic Kidney Disease Requiring Chronic Dialysis · End Stage Renal Disease on Dialysis · Sponsor: R1 Therapeutics
This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.
This description comes directly from the study's public registry record.
Clinical Trials Information · (844) 697-3339 · ClinicalTrials@r1therapeutics.com
Always discuss trial participation with your own doctor first.
| Apogee Clinical Research, LLC | Huntsville, Alabama, United States | Recruiting |
| California Institute of Renal Research | Chula Vista, California, United States | Recruiting |
| Academic Medical Research Institute | Los Angeles, California, United States | Recruiting |
| North America Research Institute | San Dimas, California, United States | Recruiting |
| Colorado Kidney Care | Denver, Colorado, United States | Recruiting |
| DaVita Clinical Research | Middlebury, Connecticut, United States | Recruiting |
| PACT Kidney Care | Orange, Connecticut, United States | Recruiting |
| US Renal Care - Fort Myers South | Fort Myers, Florida, United States | Recruiting |
| Nephrology & Hypertension Specialists | Dalton, Georgia, United States | Recruiting |
| St. Clair Nephrology Research | Shelby, Michigan, United States | Recruiting |
| DaVita Clinical Research Edina | Edina, Minnesota, United States | Recruiting |
| Johnson County Clinical Trials | Kansas City, Missouri, United States | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06712654